March 27, 2023
FinanzNachrichten
NeoGenomics, Inc.: NeoGenomics to Host Investor Day on April 4, 2023
FT. MYERS, FL / ACCESSWIRE / March 27, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of o... See more »
Morphotek: Morphotek Announces Initiation Of Phase 1 Study Of Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202 In Solid Tumors With Folate Receptor Alpha Expression
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that the first patient has been enrolled into a Phase 1 cancer study of Morphotek's antibody-drug conjugate (ADC) MORAb-202. The Phase 1 trial, which is being conducted in Japan and referred to as MORAb-202-J081-101, is a first-in-human
Read full article »
March 25, 2023
The Wall Street Journal
Regeneron, Sanofi Look for Billions From COPD Drug
The companies said Dupixent showed positive results in a late-stage study of current or former smoker... See more »
March 27, 2023
FinanzNachrichten
NeoGenomics, Inc.: NeoGenomics to Host Investor Day on April 4, 2023
FT. MYERS, FL / ACCESSWIRE / March 27, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of o... See more »
March 25, 2023
The Wall Street Journal
Regeneron, Sanofi Look for Billions From COPD Drug
The companies said Dupixent showed positive results in a late-stage study of current or former smoker... See more »
CEO
Morphotek develops biological-based products to treat cancer, inflammation and infectious diseases.
Read more